{
    "clinical_study": {
        "@rank": "23288", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined\n      with the immunoadjuvant imiquimod is safe and can induce immune responses in children with\n      recurrent ependymomas.  Eligible patients are strati\ufb01ed by primary tumor location."
        }, 
        "brief_title": "Immunotherapy for Recurrent Ependymomas in Children Treatment for Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod", 
        "condition": "Recurrent Ependymoma", 
        "condition_browse": {
            "mesh_term": "Ependymoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:  All grades of ependymoma are eligible.\n\n          -  HLA-A2 positive based on flow cytometry performed at the University of Pittsburgh.\n\n          -  Patients must have previously received standard initial therapy including attempted\n             gross total resection, where safely feasible, and in appropriate circumstances (e.g.,\n             those older than one year at initial diagnosis, with non-metastatic tumors and at\n             least microscopic residual disease), involved field fractionated radiation therapy\n             (RT) with total doses of 5000 to 6000 cGy.\n\n             \u25cfPatients must be clinically stable and off or on low \u00acdose (no more than 0.1\n             mg/kg/day, max 4 mg/day Dexam\u00acethasone) corticosteroid for at least one week prior to\n             study registration.\n\n          -  Patients must be \u2265 12 months and <22 years of age at the time of study registration.\n\n          -  Patients must have a performance status of > 70; (Karnofsky if > 16 years and Lansky\n             if < 16 years of age).\n\n          -  Patients may have non-bulky, asymptomatic metastatic disease.\n\n          -  Patients must have a life expectancy of at least 8 weeks.\n\n          -  Patients must be free of systemic infection at the time of registration and off IV\n             antibiotics for at least 7 days prior to registration.\n\n          -  Patients must have adequate organ function as measured by:\n\n               -  Bone marrow: ANC > 1,000/\u00b5l; Platelets > 100,000/\u00b5l (transfusion independent);\n                  ALC \u2265 500/\u00b5l; Hemoglobin >8 g/dl (may be transfused).\n\n               -  Hepatic: bilirubin \u2264  1.5x institutional normal for age; SGPT (ALT) < 3x\n                  institutional normal\n\n               -  Renal: Serum creatinine based on age or creatinine clearance or radioisotope GFR\n                  > 70 ml/min/1.73 m\u00b2\n\n                    -  Patients must have recovered from the toxic effects of prior therapy and be\n                       at least 3 weeks from the last dose of standard cytotoxic chemotherapy or\n                       myelosuppressive biological therapy, at least one week from the last dose\n                       of non-myelosuppressive biological therapy and at least 3 months from the\n                       completion of radiation therapy.\n\n                    -  Patients must have no overt cardiac, gastrointestinal, pulmonary, or\n                       psychiatric disease.\n\n        Patients must be willing to travel to Pittsburgh to receive the vaccine. Visits: Every 3\n        weeks x 8, then every 6 weeks x 12 depending on response/side effects\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "12 Months"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795313", 
            "org_study_id": "PRO12050422"
        }, 
        "intervention": [
            {
                "intervention_name": "HLA-A2 restricted synthetic tumor antigen", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "Imiquimod", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Reverse transcriptase-polymerase chain reaction", 
                "intervention_type": "Genetic"
            }, 
            {
                "intervention_name": "enzyme-linked immunosorbent assay", 
                "intervention_type": "Other"
            }, 
            {
                "intervention_name": "flow cytometry", 
                "intervention_type": "Other"
            }, 
            {
                "intervention_name": "immunohistochemistry staining method", 
                "intervention_type": "Other"
            }, 
            {
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Imiquimod"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 18, 2013", 
        "location": {
            "contact": {
                "email": "angela.krol@chp.edu", 
                "last_name": "Angela Krol, BSN", 
                "phone": "412-692-8047"
            }, 
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15224"
                }, 
                "name": "Children's Hospital of Pittsburgh of UPMC"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Immunotherapy for Recurrent Ependymomas in Children Treatment for Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod", 
        "overall_contact": {
            "last_name": "Regina Jakacki, MD", 
            "phone": "412-692-7056"
        }, 
        "overall_official": {
            "last_name": "Regina I Jakacki, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Grade 3 or 4 non-hematological toxicities.", 
            "measure": "Number of Participants with unacceptable toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795313"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Children's Hospital of Pittsburgh", 
            "investigator_full_name": "Regina Jakacki", 
            "investigator_title": "MD, Professor of Pediatrics, Director, Pediatric Neuro-Oncology Program", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Tumor-associated antigen-specific T-cell", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Children's Hospital of Pittsburgh", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Children's Hospital of Pittsburgh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}